Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in miceResearch in context
Petr Kosztyu,
Milan Kuchar,
Jiri Cerny,
Lucia Barkocziova,
Michal Maly,
Hana Petrokova,
Lydie Czernekova,
Veronika Liskova,
Leona Raskova Kafkova,
Pavlina Knotigova,
Josef Masek,
Jaroslav Turanek,
Petr Maly,
Milan Raska
Affiliations
Petr Kosztyu
Department of Immunology, Palacky University in Olomouc, Hnevotinska 3, Olomouc 779 00, Czech Republic
Milan Kuchar
Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Prumyslova 595, Vestec 252 50, Czech Republic
Jiri Cerny
Laboratory of Structural Bioinformatics of Proteins, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Prumyslova 595, Vestec 252 50, Czech Republic
Lucia Barkocziova
Department of Immunology, Palacky University in Olomouc, Hnevotinska 3, Olomouc 779 00, Czech Republic
Michal Maly
Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Prumyslova 595, Vestec 252 50, Czech Republic
Hana Petrokova
Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Prumyslova 595, Vestec 252 50, Czech Republic
Lydie Czernekova
Department of Immunology, Palacky University in Olomouc, Hnevotinska 3, Olomouc 779 00, Czech Republic
Veronika Liskova
Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Prumyslova 595, Vestec 252 50, Czech Republic
Leona Raskova Kafkova
Department of Immunology, Palacky University in Olomouc, Hnevotinska 3, Olomouc 779 00, Czech Republic
Pavlina Knotigova
Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Hudcova 70, Brno 621 00, Czech Republic
Josef Masek
Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Hudcova 70, Brno 621 00, Czech Republic
Jaroslav Turanek
Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Hudcova 70, Brno 621 00, Czech Republic; Corresponding authors.
Petr Maly
Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Prumyslova 595, Vestec 252 50, Czech Republic; Corresponding authors.
Milan Raska
Department of Immunology, Palacky University in Olomouc, Hnevotinska 3, Olomouc 779 00, Czech Republic; Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Hudcova 70, Brno 621 00, Czech Republic; Correspondence to: Palacky University in Olomouc, Hnevotinska 3, Olomouc 779 00, Czech Republic.
Background: The development of an effective vaccine preventing HIV-1 infection is hindered by the enormous antigenic variability and unique biochemical and immunological properties of HIV-1 Env glycoprotein, the most promising target for HIV-1 neutralizing antibody. Functional studies of rare elite neutralizers led to the discovery of broadly neutralizing antibodies. Methods: We employed a highly complex combinatorial protein library derived from a 5 kDa albumin-binding domain scaffold, fused with support protein of total 38 kDa, to screen for binders of broadly neutralizing antibody VRC01 paratope. The most specific binders were used for immunization of experimental mice to elicit Env-specific antibodies and to test their neutralization activity using a panel of HIV-1 clade C and B pseudoviruses. Findings: Three most specific binders designated as VRA017, VRA019, and VRA177 exhibited high specificity to VRC01 antibody. Immunized mice produced Env-binding antibodies which neutralize eight of twelve HIV-1 Tier 2 pseudoviruses. Molecular modelling revealed a shape complementarity between VRA proteins and a part of VRC01 gp120 interacting surface. Interpretation: This strategy based on the identification of protein replicas of broadly neutralizing antibody paratope represents a novel approach in HIV-1 vaccine development. This approach is not affected by low immunogenicity of neutralization-sensitive epitopes, variability, and unique biochemical properties of HIV-1 Env used as a crucial antigen in the majority of contemporary tested vaccines. Fund: Czech Health Research Council 15-32198A, Ministry of Health, Czech Republic. Keywords: Neutralizing antibody, Albumin-binding domain scaffold, Combinatorial protein library, Antibody paratope mimetics, Protein docking, HIV-1 vaccine